Economic evaluation of different hormonal therapies for prostate cancer. Final results from the Quality of Life Antiandrogen Blockade Italian Observational Study (QuABIOS)

Archivio Italiano di Urologia e Andrologia

Volumn 79, Issue 3, 2007, Pages 104-107

  Lazzaro, Carlo ^a   Bartoletti, Riccardo ^b   Guazzoni, Giorgio ^c   Orestano, Fausto ^d   Pappagallo, Giovanni L ^e   Prezioso, Domenico ^f   Zattoni, Filiberto ^a  

^a Univ Firenze ^*  (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Casa di Cura Orestano   (Italy)

^d Az Osp De Lellis   (Italy)

^e Pol Univ GB Rossi   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cost minimization analysis; Cyproterone acetate; Prostate cancer; QuABIOS

Indexed keywords

BICALUTAMIDE; CYPROTERONE ACETATE; GONADORELIN DERIVATIVE;

ARTICLE; BOOTSTRAPPING; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; STATISTICAL SIGNIFICANCE;

ANDROGEN ANTAGONISTS; COSTS AND COST ANALYSIS; HUMANS; MALE; PROSTATIC NEOPLASMS; QUALITY OF LIFE;

EID: 35948994544     PISSN: 11243562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Rosso S, Spitale A, Balzi D, Franceschi S, Zanetti R. Estimate of cancer incidence in Italian regions, 2001. Epidemiol Prev 2004; 28:247
2. AIRT Working Group. Italian cancer figures-report 2006: 1. Incidence, mortality and estimates. Epidemiol Prev. 2006 Jan-Feb; 30(1 Suppl 2):8-10, 12-28, 30
3. Cancer Trends Progress Report - 2005 Update. Available at: http://progressreport.cancer.gov. (Accessed October 26, 2006)
4. Scattoni V, Lazzaro C, Rigatti P. The economics of managing patients with prostate cancer. Arch Ital Urol Androl 2003; 75:75
5. Prezioso D, Pappagallo GL, Guazzoni G, Orestano F, Zattoni F. QuABIOS Group. Hormonal treatment for prostate cancer in Italy. Preliminary data from a survey of the QuABIOS Group. Arch Ital Urol Androl 2006; 78.15
6. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EurosQol: Results from a UK general population survey. York: University of York, Discussion Paper No. 138, 1995
7. EuroQol Group. EurosQol - a new facility for the measurement of health-related quality of life. Health Pol 1990; 16:199
8. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
9. rd ed. Oxford: Oxford University Press, 2005
10. O'Brien B, Levine M, Willan A, Goeree R, Haley S, Blockhouse G, Gent M. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. Arch Intern Med 1999; 159:2298
11. OEMF-Masson. L'Informatore Farmaceutico. 66∧ edizione. Milano: Masson-OEMF, 2006
12. Agenzia Italiana del Earmaco, Direzione Generale - Ministem della Salute. Osservatorio Nationale sull'Impiego dei Medicinali. L'uso dei Farmaci in Italia. Rapporta nazionale anno 2005 Roma: Ministero della Salute. Osservatorio Nazionale sull'Impiego dei Medicinali, Giugno 2006
13. Ministero della Sanità. Direzione generale della programmazione sanitaria. Decreto ministeriale 28 maggio 1999, n. 329. Regolamento di aggiornamento del decreto ministeriale 28 maggio 1999, n. 329, recante norme di individuazione delle malattie croniche e invalidanti ai sensi dell'articolo 5, comma 1, lettera a) del decreto legislativo 29 aprile 1998 n.124. Supplemente Ordinario Gazzetta Ufficiale n. 226 del 25 settembre 1999 - Serie Generale
14. nd ed. Brooks/Cole, 2000.
15. a ed). Napoli: Idelson-Gnocchi, 2003, p. 217-228
16. Desgagné A, Castilloux AM, Angers JF, LeLorier J. The use of bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. PharmacoEconomics 1998; 13:487
17. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med. 2000; 19:3219
18. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Chapman and Hall: New York, 1993
19. Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ 1998; 7:723
20. Lazzaro C per il GISESCaPI. Managing patients with prostate cancer in Italy during the first year after diagnosis. A cost description based on a sample of 8 urological wards. Arch Ital Urol Androl 2003; 75:138